Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28741130 | 0.89 | — | — | |
| SCHEMBL28698314 | 0.89 | — | — | |
| SCHEMBL7193917 | 0.89 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAADRB2ADRB1ADRB3 | |
| SCHEMBL21570116 | 0.89 | — | — | |
| SCHEMBL7184412 | 0.85 | CHRM2 (0.36) | SMN1; SMN2LMNACES2CES1ADRB2 | |
| SCHEMBL1421696 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNACES2CES1ADRB2 | |
| SCHEMBL10650039 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNACES2CES1ADRB2 | |
| SCHEMBL10260369 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNACES2CES1ADRB2 | |
| SCHEMBL10260332 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNACES2CES1ADRB2 | |
| SCHEMBL1880760 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNACES2CES1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832077-B1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARM CO (US) | 2001-11-14 | — | — | EP | claimed |
| US-5961483-A | Iontophoretic delivery of cell adhesion inhibitors | COLLATERAL AGENTS, LLC | 1999-10-05 | — | — | US | claimed |
| US-5811441-A | INHIBITION OF PLATELET AGGREGATION; TREATMENT OF AUTOIMMUNE DISEASES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | claimed |
| EP-0832077-A1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997048444-A1 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | BECTON DICKINSON AND COMPANY (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1996037482-A1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| CN-119977858-A | Preparation method of hydroxy pinacolone retinoic acid ester | 珠海市柏瑞医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-104640843-A | 1-(cycloalkyl-carbonyl)proline derivative | DAINIPPON SUMITOMO PHARMA CO | 2015-05-20 | — | — | CN | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
| EP-0920345-A4 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | VYTERIS INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-0832077-B1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARM CO (US) | 2001-11-14 | — | — | EP | disclosed |
| US-5961483-A | Iontophoretic delivery of cell adhesion inhibitors | COLLATERAL AGENTS, LLC | 1999-10-05 | — | — | US | disclosed |
| US-5935598-A | DEVICE FOR NON-INVASIVE ADMINISTRATION OF A CELL ADHESION RECEPTOR ANTAGONIST TO A MAMMAL; CURRENT DISTRIBUTING MEMBER, IONIZABLE ANTAGONIST RESERVOIR, ELECTROLYTE RESERVOIR, POWDER SOURCE; TREATING THROMBOSIS, ANTICOAGULANTS | BECTON DICKINSON RESEARCH CENTER (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0920345-A1 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | Becton Dickinson and Company (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5811441-A | INHIBITION OF PLATELET AGGREGATION; TREATMENT OF AUTOIMMUNE DISEASES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0832077-A1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997048443-A1 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | BECTON DICKINSON AND COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048444-A1 | IONTOPHORETIC DELIVERY OF CELL ADHESION INHIBITORS | BECTON DICKINSON AND COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1996037482-A1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | SMN1; SMN2 900/4885LMNA 3723/4885CES2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.